PDCD1 and B-cell chronic lymphocytic leukemia: PD-L1 expression on macrophages also promotes an M2 phenotype, contributing to immune evasion, but blocking the PD-1/PD-L1 pathway with ibrutinib could reverse these dysfunctions and restore the metabolic and antitumor activity of monocytes/macrophages in CLL [85].